mycoses1'^. In addition, orally administered FLCZhas been reported to be useful for a systemic therapy of dermatophytoses, oropharyngeal candidiosis and other superficial mycoses3~6).
Methods for the susceptibility test of yeast to antifungal agents have been standardized by the National Committee for Clinical Laboratory Standards7), while the standard method has not yet been established for the filamentous fungi. Furthermore, the in vitro activity of azole antifungal agents is known to be affected by various assay conditions8^12). For these reasons, measuring the in vivo activity of azole antifungal agents in suitable animal models is essential for predicting the clinical efficacy of those agents against mycoses caused by filamentous fungi.
In the present study, the therapeutic efficacy of orally administered FLCZwas studied in a guinea pig model of tinea corporis that has been successfully used in our laboratory for evaluating the in vivo activity of several antifungal agents on dermatophytes13~16). Griseofulvin (GRF) which has long been clinically used for a systemic therapy of dermatophytosis was chosen as a reference drug.
Materials and Methods
Antifungal Agents FLCZ (Pfizer Pharmaceuticals Inc.) and GRF (Sigma) determined with an ATP bioluminescence assay17) were 1 and 0.25 /ig/ml, respectively.
The testing strain was grown on modified 1/10 Sabouraud dextrose agar and conidia were prepared as described in our previous paper15).
Infection Method
The guinea pigs were infected with the inoculum using a previously described method13~16). Hair was removed from the entire surface of each animal's back with electric hair clippers, and a circular spot of 2cm in diameter in the center of the back was designated the inoculation site. Then a procedure in which tape was stuck on the inoculation site and forcefully removed was repeated several times. The short hairs remaining after that were pulled out with tweezers. When the hairs were pulled out locally in the inoculation site, the upper stratum corneum of the epidermis was also removed. Then 60jal (Ll X l06 conidia) ofinoculum was applied to each spot. On the 5th day after infection, at which time lesions had clearly developed at the inoculation sites, 10 infected animals each were randomly allocated to the following 6 groups: (1) On the 4th day after the final drug administration, culture study was performed according to the method as described previously1 5).
The therapeutic efficacy in each group was assessed based on the culture study results for each animal overall and those for the fragments of skin tissue from each animal. Twoindices were used to make this assessment: (1) the negative culture rate for each group (the percentage of animals in the group whose tissue fragments were all culture-negative), and (2) the mean fungal burden for each group (the mean number of culture-positive tissue fragments for 10 tissue fragments in the group).
To compare the therapeutic efficacy among different animal groups, a multiple comparison analysis of the infection intensity results was performed. First, the Kruskal-Wallis test was done. Then a multiple comparison (nonparametric) using the Bonferroni inequality was performed for groups in which a significant difference (P<0.01) was shown by the Kruskal-Wallis test. Six animals that died during the study were excluded from the statistical analysis. Three of the animals (one each in the FLCZ 4-mg and 16-mg groups, and one in the GRF 100-mggroup) probably died because of dosing errors, and the other three (all in the GRF 100-mg group) probably because of weakness caused by gastrointestinal symptoms.
Results and Discussion
Once a day treatment with FLCZor GRFwas begun on the 5th day after the animals in the 6 groups (control, FLCZ 1 mg, FLCZ 4mg, FLCZ 16mg, GRF 25mg, GRF lOOmg)
were infected with T. mentagrophytes and was continued for 14 days. Therapeutic efficacy was assessed by culture study performed at the end of the observation period (the 18th day post infection). The results are shown in Table 1 . In the control group, skin lesions were confirmed on the 4th or 5th day post infection.
The lesions gradually worsened, and crusts appeared on the 9th to llth day post infection. The pathological signs persisted until almost the end of the observation period. Consistent with the development of the lesions, they yielded a high culture score of +9.9.
Although there were some intragroup differences between individual animals in all the FLCZ and GRF groups, the highest FLCZ dose and both GRF doses resulted in significantly decreased meanvalues of culture score. In the FLCZ1-mg and 4-mg groups, none of animals was culture-negative, and the meanculture scores were as high as +8.4 and +9.3, respectively.
Moreover, neither of these groups showed a significant therapeutic effect compared to the control group. In the FLCZ16-mg group, however, 2 of the 9 animals became culture-negative (mycologically cured), and the meanculture score was only + 1.8, which was significantly low when compared not only with the value for the control group (P<0.01) but also with the values for the FLCZ 1-mg group (P<0.05) and 4-mg group (P<0.01). As for the GRFgroups, the mean culture scores were significantly lower than that of the control group; the score was +2.5 (P<0.01) for the GRF 25-mg group and +2.3 CP<0.05)
for the GRF 100-mg group. Although many antifungal agents have become available for the topical treatment of dermatophytosis, there are still few oral antifungals that can be used for systemic therapy. Twotriazole antifungal agents FLCZ and itraconazole (ITCZ) were successfully developed in recent years. These triazoles are better tolerated and active against a broader range of pathogenic fungi than GRF, whose activity is almost limited to dermatophytes21). In particular, FLCZis in the widest use, mainly for a treatment of disseminated candidiasis, cryptoccosis and some other deep-seated mycoses because of its high safety and excellent pharmacokinetic characteristics.
To evaluate the potential usefulness of oral FLCZfor the treatment of dermatophytosis at the preclinical stage, the therapeutic efficacy of oral FLCZwas compared with that of oral GRFin a guinea pig model ofdermatophytosis. This model has been used to evaluate the in vivo effect of a variety of antifungal agents on dermatophytosis13~16). The favorable reliability and objectiveness of this evaluation system appear to be due to partly, at least, introducing a sequantitative mycological assessment criterion.
The results of the present study show that oral administration of FLCZ in the 16-mg group had a significant (P<0.0\) therapeutic effect compared to the control group, and that the effectiveness obtained in the FLCZ16-mg group was approximately equal to that in the GRF 25-mg and 100-mg groups (P>0.05). Richardson et al. reported that a significant mycological therapeutic effect was seen after once-a-day oral administration of FLCZat a daily dosage of 5mg/kg for 10days in a guinea pig model of dermatophytosis similar to that used in the present study22). These results cannot be directly compared with ours because duration of administration and the assessment criteria were different in Richardson's study. Nevertheless, the results of the two studies seem to be basically the same, 209 even though the significantly high therapeutic effect was only seen at a higher dose in our study. showing high transfer of FLCZto skin and related tissues including the stratum corneum, epidermis-dermis, and nails23~25). Faergemann reported that when 50-mg dose of FLCZonce a day was orally administered to humans for 12 days, the FLCZconcentration in the stratum corneumof skin on the back was greater than that in serum, and the drug concentration in the stratum corneum 4 and 7 days after the final administration was still 19.9/ig/g and 5.8
/Lig/g, respectively2^.
Considering a good efficacy in animal models, along with an excellent pharmacokinetics and low toxicity in humans, orally administered FLCZis expected to have a high clinical usefulness in a treatment of dermatophytosis and further clinical studies are warranted.
